Since myeloablative pre-treatment targets bone marrow cells rather than those already in the bloodstream there wouldn't be a difference in already existing CD4+.memory cells. Post transplant unless transplanted with CD32 variant marrow any standard marrow would still produce CCR5 expressing cells.